Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Inhibits
  • Induces
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Oncovin, Vincristin; Belgium: Vincrisin; Bulgaria: Cytocristin; Czech Republic: Vincristine; Denmark: Oncovin; Finland: Oncovin; France: Oncovin, Vincristine; Germany: Cellcristin, Vincristin; Greece: Oncovin, Vincristine; Hungary: Vincristin; Ireland: Vincristine; Italy: Oncovin, Vincristina; Latvia: Vincristin; Lithuania: Oncrivin, Vincristine; Luxembourg: Oncovin, Vincristine, Vincristinum; Netherlands: Vincristine; Poland: Oncovin, Vincristin; Portugal: Vincristina; Romania: Sindovin; Slovakia: Vincristin; Spain: Vincristina, Vincrisul; Sweden: Oncovin, Vincristine; UK: Vincristine.

North America

Canada: Vincristine; USA: Vincristine.

Latin America

Argentina: Vincristina; Brazil: Oncovin, Tecnocris, Vincizina, Vincristin; Mexico: Citomid, Crivosín, Oncovín, Vincristina.


Japan: Oncovin.

Drug combinations


Vincristine Sulfate: C~46~H~56~N~4~O~10~ H~2~SO~4~. Mw: 923.04. (1) Vincaleukoblastine, 22-oxo-, sulfate (1:1); (2) Leurocristine sulfate (1:1). CAS-2068-78-2; CAS-57-22-7 (vincristine)(1962).

Pharmacologic Category

Antineoplastic Agents; Plant Alkaloids and Other Natural Products. Vinca Alkaloid. (ATC-Code: L01CA02).

Mechanism of action

Binds to tubulin and inhibits microtubule formation, therefore arresting cell at metaphase by disrupting formation of mitotic spindle. May also interfere with nucleic acid and protein synthesis by blocking glutamic acid utilization.

Therapeutic use

Treatment of leukemias, Hodgkin’s disease, non-Hodgkin lymphomas, Wilms’ tumor, neuroblastoma, rhabdomyosarcoma.

Pregnancy and lactiation implications

May cause fetal harm. Teratogenicity and embryolethality demonstrated in animals. Pregnancy should be avoided during therapy.

Unlabeled use


Hypersensitivity to vincristine or any component of the formulation. Patients with demyelinating form of Charcot-Marie-Tooth syndrome. Pregnancy.

Warnings and precautions

Hazardous agent. Constipation and/or paralytic ileus may occur. Alterations in mental status (depression, confusion, or insomnia) may occur. Neurologic effects may be additive with those of other neurotoxic agents and spinal cord irradiation. Respiratory effects (shortness of breath and bronchospasm) might occur (especially in combination with mitomycin C). Urinary tract disturbances may occur. Use with caution in hepatic impairment, pre-existing neuromuscular disease, and in the elderly. Not for intrathecal use (caused severe neurologic damage and/or death). For I.V. use only. Vincristine is a vesicant (avoid extravasation).



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart